Trillium Therapeutics’ (TR) “Neutral” Rating Reiterated at HC Wainwright

Share on StockTwits

Trillium Therapeutics (TSE:TR) (NASDAQ:TRIL)‘s stock had its “neutral” rating reiterated by equities researchers at HC Wainwright in a research note issued to investors on Monday, Zacks.com reports.

Trillium Therapeutics has a 12-month low of C$28.50 and a 12-month high of C$39.45.

Trillium Therapeutics Company Profile

Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. The Company leads program, TTI-621, which is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1).

Recommended Story: Buy-Side Analysts

Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Family Management Corp Grows Stake in FedEx Co.
Family Management Corp Grows Stake in FedEx Co.
Blackrock Muniyield Insured Fund Inc.  Stake Lifted by Family Management Corp
Blackrock Muniyield Insured Fund Inc. Stake Lifted by Family Management Corp
Family Management Corp Grows Stock Holdings in iShares Core S&P Small-Cap ETF
Family Management Corp Grows Stock Holdings in iShares Core S&P Small-Cap ETF
Walt Disney Co  Shares Sold by Family Management Corp
Walt Disney Co Shares Sold by Family Management Corp
Family Management Corp Has $2.66 Million Position in SPDR S&P 500 ETF Trust
Family Management Corp Has $2.66 Million Position in SPDR S&P 500 ETF Trust
Pimco Total Return ETF  is Family Management Corp’s 3rd Largest Position
Pimco Total Return ETF is Family Management Corp’s 3rd Largest Position


© 2006-2019 Ticker Report